深賽格(000058.SZ):擬公開發行不超7億元公司債券
格隆匯12月9日丨深賽格(000058.SZ)公佈,為滿足公司主營業務發展過程中的資金需求,進一步拓寬公司融資渠道,公司擬通過深圳證券交易所在國內資本市場公開發行公司債券,此次債券發行規模為不超過人民幣7億元(含),可分期發行。
具體發行規模提請股東大會授權董事會或董事會獲授權人士依據國家法律、法規及證券監管部門的有關規定,根據公司資金需求和發行時市場情況在前述範圍內確定。
債券募集資金,扣除發行費用後,可用於補充流動資金,償還公司有息債務、項目投資、收購資產及適用的法律法規允許的其他用途。具體用途提請股東大會授權公司董事會或董事會授權人士根據公司財務狀況與資金需求情況,在上述範圍內確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.